B&K Corp Ltd (02396.HK)

B&K Corp. Ltd. engages in the research, development, discovery and commercialization of systematic and integrated biomacromolecule therapeutic drugs for a multiple diseases, including thermal burns, DFUs, pressure ulcers, hemorrhoids, photodermatitis, radiation ulcers, fresh wounds, gastric ulcers, dry eye syndrome, corneal injury, and alopecia. The company is headquartered in Qingdao, Shandong and currently employs 100 full-time employees. The company went IPO on 2025-12-22. The firm committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The firm primarily focus on the discovery, development and commercialization of therapies for wound healing, currently platelet-derived growth factor (PDGF) drugs. The firm mainly operates its businesses in the domestic market.